NDAORALCAPSULE, EXTENDED RELEASE
Approved
Aug 2013
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
20
Data completeness
6/8 — Strong
TROKENDI XR (topiramate) by Supernus Pharmaceuticals is cytochrome p450 3a4 inducers [moa]. Approved for epilepsy, migraine, seizures and 1 more indications. First approved in 2013.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TROKENDI XR is an extended-release oral capsule formulation of topiramate, a cytochrome P450 3A4 inducer approved by the FDA in August 2013. It is indicated for the treatment of epilepsy and migraine prophylaxis. The product represents a branded, sustained-release alternative to immediate-release topiramate formulations, offering improved dosing convenience for patients requiring long-term anticonvulsant or migraine preventive therapy.
$0.0BPart D
1.9 years to LOEMechanism of Action
Cytochrome P450 3A4 Inducers
Indications (4)
Worked on TROKENDI XR at Supernus Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.